Who we are
Veldana Medical SA is a Swiss company based in Morges, on the shore of the Lake Geneva.
Veldana Medical SA (earlier Wallsten Medical SA) was founded in the 90’s to develop, produce and commercialise a minimally invasive method for the treatment of Heavy Menstrual Bleeding (HMB) – more specifically Dysfunctional Uterine Bleeding – invented by the Swedish Engineer Hans Wallstén. This medical device was named Cavaterm™.
The benefits of the Cavaterm™ system as a safe and easy-to-use method to treat DUB soon convinced physicians all over Europe, then overseas. Their feedback allowed further product developments for an ongoing product evolution based on users’ needs and wishes.
Today Cavaterm™ is recognised as a method of choice for the treatment of DUB by healthcare professionals offering minimally invasive therapies and using the most sofisticated technologies.
What we do
All research and development leading to production follow-up and product updates is performed in our laboratory by qualified and experienced engineers.
Veldana Medical SA owns a clean room and a factory for the production of Cavaterm™ catheters and central units. All products are manufactured, calibrated and controlled on site in Morges.
Product training, information, communication, promotion and distribution is performed by our sales and marketing department. Veldana Medical is represented worldwide by exclusive distributors appointed in different countries or areas.
Our structure also covers customer service, supply chain, logistics, quality assurance, clinical and regulatory affairs, HR, IT, finance and administration services.
2019 : ACUBLO™ a single use disposable accessory for laparoscope designed to keep a clear view of the surgical site is launched.
2018: Cavaterm™ 3.1, which is the new generation of the Cavaterm™ Central Unit is launched on the worldwide market.
2012: Pnn Medical SA is acquired by CHEMO Group and change its name to Veldana Medical SA.
2010: A year after the demerge from Pnn Medical A/S, Pnn Medical SA renews its company and product logos, as well as its corporate identity.
2009: Cavaterm™ 3, which is the third generation of the Cavaterm™ Central Unit is launched on the worldwide market. Pnn Medical SA is demerged from the umbrella organization Pnn Medical A/S. A local Swiss Management Team is now in charge, supervised by a professional team of Board of Directors.
2007: The merged companies change name to Pnn Medical. Pnn is the Latin abbreviation for “primum non nocere”, which means “First, do no harm”.
2005: Merger between Wallsten Medical SA and Engineers & Doctors A/S.
2004: Launch of the second generation of the Cavaterm™ Central Unit.
2001: Launch of the Cavaterm™ plus catheter, which keeps the orginal product features but has added features for optimised safety, comfort and ease-of-use.
1995: CE Mark obtained for the Cavaterm™ system. First introduction to the market.
1993: First clinical trial with Cavaterm™ in the University Hospital of Lund, Sweden, which will be followed by a second clinical trial in the CHUV University Hospital of Lausanne, Switzerland, less than a year later.
1990: Packard Development SA is founded by the Swedish engineer Hans Wallstén. This company is created to develop and commercialise a medical device for the treatment of Dysfunctional Uterine Bleeding (DUB) invented by Hans Wallstén. The product is named Cavaterm™. Later the company name will be changed to Wallsten Medical SA. The name will change again in 2007 and become Pnn Medical SA.
Veldana Medical SA is committed to improve Quality of Life for women by offering Minimally Invasive Therapies.
Using best practice methods in research, development, production, distribution, and product training we are providing world wide access to Gold Standard medical equipment with focus on product quality, patient safety, and procedure efficacy.
Our goal is to support healthcare professionals optimising clinical results and satisfaction for women treated with our products.
Presently we have no vacant position.
Please feel free to send your resume and we will contact you as soon as we will have an opportunity matching your qualifications.